Recent regulatory approval of multiple bispecific antibody (BsAb) constructs has intensified efforts toward development of these complicated biologics. As each molecule contains multiple functional domains that interact with corresponding disease-related targets, BsAbs represent an expansive, diverse family of molecules offering potential benefits beyond those of traditional monoclonal antibodies (mAb). Download our white paper to learn about a purposeful approach to different aspects of bioanalysis for BsAbs.